We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$14.8M
Cap. Flow
-$12.1M
Cap. Flow %
-9.06%
Top 10 Hldgs %
36.98%
Holding
83
New
24
Increased
11
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.46M
2
ARVN icon
Arvinas
ARVN
+$5.31M
3
HUM icon
Humana
HUM
+$4.85M
4
SLNO
Soleno Therapeutics
SLNO
+$4M
5
RLAY icon
Relay Therapeutics
RLAY
+$3.64M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$6.55M
2
TGTX icon
TG Therapeutics
TGTX
+$4.86M
3
ALGN icon
Align Technology
ALGN
+$4.76M
4
CI icon
Cigna
CI
+$4.23M
5
BNTX icon
BioNTech
BNTX
+$4.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.08B
$2.15M 1.61%
+699,698
New +$2.44M
IONS icon
27
Ionis Pharmaceuticals
IONS
$8.93B
$2.15M 1.61%
+61,367
New +$2.29M
PEN icon
28
Penumbra
PEN
$12.6B
$2.14M 1.61%
+9,000
New +$2.05M
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$343M
$2.01M 1.51%
+159,552
New +$2.4M
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$1.91M 1.43%
68,608
-8,492
-11% -$257K
RDY icon
31
Dr. Reddy's Laboratories
RDY
$9.8B
$1.86M 1.39%
117,500
-64,000
-35% -$961K
ONC
32
BeOne Medicines Ltd
ONC
$33.9B
$1.85M 1.39%
10,000
-5,300
-35% -$1.08M
ETNB
33
DELISTED
89bio
ETNB
$1.76M 1.32%
225,323
-75,277
-25% -$620K
TARS icon
34
Tarsus Pharmaceuticals
TARS
$2.55B
$1.56M 1.17%
28,178
-17,422
-38% -$791K
PLRX icon
35
Pliant Therapeutics
PLRX
$65M
$1.36M 1.02%
103,504
-46,096
-31% -$629K
FULC icon
36
Fulcrum Therapeutics
FULC
$241M
$1.33M 1%
+283,599
New +$1.05M
STOK icon
37
Stoke Therapeutics
STOK
$1.84B
$1.25M 0.94%
113,096
-63,504
-36% -$780K
LEGN icon
38
Legend Biotech
LEGN
$3.65B
$1.22M 0.92%
37,600
-9,400
-20% -$389K
TECX
39
Tectonic Therapeutic
TECX
$536M
$1.2M 0.9%
26,081
-10,263
-28% -$434K
ALVO icon
40
Alvotech
ALVO
$1.19B
$1.19M 0.9%
90,100
– –
YARW
41
Yarrow Bioscience, Inc. Common Stock
YARW
$20.3M
$1.18M 0.89%
7,069
– –
ELDN icon
42
Eledon Pharmaceuticals
ELDN
$255M
$1.06M 0.79%
+256,373
New +$1.01M
BHVN icon
43
Biohaven
BHVN
$2.02B
$1.05M 0.79%
+28,159
New +$1.31M
GOSS icon
44
Gossamer Bio
GOSS
$101M
$993K 0.75%
1,097,999
+629,500
+134% +$539K
ACRS icon
45
Aclaris Therapeutics
ACRS
$715M
$966K 0.73%
+389,333
New +$969K
ANNX icon
46
Annexon
ANNX
$796M
$743K 0.56%
+144,830
New +$891K
VERU icon
47
Veru
VERU
$35.5M
$740K 0.56%
+111,760
New +$829K
SLRN
48
DELISTED
ACELYRIN
SLRN
$736K 0.55%
+234,435
New +$1.14M
REPL icon
49
Replimune Group
REPL
$455M
$663K 0.5%
+54,738
New +$665K
ESTA icon
50
Establishment Labs
ESTA
$2.71B
$604K 0.45%
13,100
-8,600
-40% -$375K
1
2
3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
EWM
Evergreen Wealth Management Williamston, Michigan $194M AUM 13.93% 1-Year Est. Return

Exome Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Exome Asset Management held 83 positions worth $133M, down 10% from $148M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Exome Asset Management withdrew a net $12.1M in Q4 2024, closing 24 positions and reducing 18 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $6.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Exome Asset Management opened a new position in Syndax Pharmaceuticals worth $4.22M.

  • Exome Asset Management's largest Q4 2024 buy was Syndax Pharmaceuticals: 318,900 shares worth $4.22M.
  • Exome Asset Management added most to Relay Therapeutics in Q4 2024, an estimated $3.64M increase.
  • Exome Asset Management's biggest Q4 2024 reduction was Mersana Therapeutics, cutting an estimated $2.08M.
  • Exome Asset Management fully exited Ascendis Pharma A/S in Q4 2024, selling an estimated $6.55M.
  • Exome Asset Management's ten largest holdings make up 37% of its $133M portfolio in Q4 2024.
  • Exome Asset Management opened 24 new positions and closed 24 in Q4 2024.
  • Exome Asset Management's portfolio value fell 10% quarter-over-quarter to $133M.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.